Global gastric cancer therapeutics market is anticipated to show a robust growth in the upcoming five years, 2022-2026. The market is expected to show an impressive growth of CAGR in the forecast period owing to the rising cases of cancer and limited amount of effective drugs. Moreover, the research and development that is consistently being conducted by various research institutes and labs is expected to drive the growth of global gastric cancer therapeutics market in the next five years.

Also, the growing prevalence of lymphoma, adenocarcinoma, gastrointestinal stromal tumors, carcinoid tumors, etc. are also driving the growth of the global gastric cancer therapeutics market. Treatment for gastric cancer basically depends upon the stage of cancer. Various treatment methods are available such as surgery, targeted drugs, chemotherapy, etc. The factors that propel the growth of the global gastric cancer therapeutics market include innovations in treatment, a growing number of cancer treatment centers, increasing research and development activities, and combination therapies.

The global gastric cancer therapeutics market is segmented on the basis of therapy type, disease indication, molecule type, line of therapy, mode of action, route of administration, end user, distribution channel, competitive landscape, and regional distribution. Based on therapy type the market is further bifurcated into Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Surgery. Targeted therapy is anticipated to hold the largest share of the market in the forecast period. The growth can be attributed to the delivery of advanced technological approaches like stem cell therapy, etc. Chemotherapy is also anticipated to hold the significant amount of market share owing to its efficiency in controlling the growth of the cancerous cells and thus have proved to be quite beneficial.

Some of the major competitors in the market are Bristol-Myers Squibb AB, Celltrion Inc., Eli Lilly and Company, Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Imugene Limited, Novartis AG, Merck & Co. Inc., Otsuka Holdings Co. Ltd, Pfizer Inc., Array Biopharma Inc., AstraZeneca PLC, Ipsen Biopharmaceuticals Ltd., Taiho Oncology Inc., Galena Biopharma Inc., among others.

Years considered for this report:

Historical Years: 2016 – 2019

Base Year: 2020

Estimated Year: 2021

Forecast Period: 2022 – 2026

Objective of the Study:

  • To analyze the historical growth of the market size of global gastric cancer therapeutics market from 2016 to 2020.
  • To estimate and forecast the market size of global gastric cancer therapeutics market from 2021 to 2026 and growth rate until 2026. 
  • To classify and forecast global gastric cancer therapeutics market based on therapy type, disease indication, molecule type, line of therapy, mode of action, route of administration, end user, distribution channel, competitional landscape, and regional distribution.
  • To identify dominant region or segment in the global gastric cancer therapeutics market.
  • To identify drivers and challenges for global gastric cancer therapeutics market.
  • To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in global gastric cancer therapeutics market.
  • To identify and analyze the profile of leading players operating in global gastric cancer therapeutics market.
  • To identify key sustainable strategies adopted by market players in global gastric cancer therapeutics market.


Click here to download the sample

TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of manufacturers, suppliers, and service providers across the globe. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the manufactures which could not be identified due to the limitations of secondary research. TechSci Research analyzed the manufactures, distribution channels and presence of all major players across the globe.

TechSci Research calculated the market size of global gastric cancer therapeutics market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by TechSci Research.

Key Target Audience:

  • Manufacturers, end users, service providers and other stakeholders
  • Distributers and suppliers of gastric cancer therapeutics and other stakeholders
  • Organizations, forums, and alliances related to gastric cancer therapeutics market  
  • Market research and consulting firms

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as vendors, suppliers, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope:

In this report, global gastric cancer therapeutics market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

  • Global Gastric Cancer Therapeutics Market, By Therapy Type:
    • Chemotherapy
    • Targeted Therapy
    • Immunotherapy
    • Radiation Therapy
    • Surgery
  • Global Gastric Cancer Therapeutics Market, By Disease Indication:
    • Gastric Adenocarcinoma
    • Gastrointestinal Stromal Tumor (GIST)
    • Gastric Neuroendocrine Tumors (gNET)
  • Global Gastric Cancer Therapeutics Market, By Molecule Type:
    • Small Molecule
    • Biologics
  • Global Gastric Cancer Therapeutics Market, By Line of Therapy:
    • Neoadjuvant and Adjuvant
    • First Line Therapy
    • Second Line Therapy
  • Global Gastric Cancer Therapeutics Market, By Mode of Action:
    • Programmed Cell Death Protein 1 (PD-1) Inhibitors
    • Human Epidermal Growth Factor Receptor (HER2) Antagonists
    • Vascular Endothelial Growth Factor Receptor (VEGFR) Antagonists
    • Others
      • Microtubule Inhibitors
      • Kinase Inhibitors
  • Global Gastric Cancer Therapeutics Market, By Route of Administration:
    • Oral
    • Parenteral
  • Global Gastric Cancer Therapeutics Market, By End User:
    • Hospitals
    • Specialty Clinics
    • Ambulatory Surgical Centers
    • Others
  • Global Gastric Cancer Therapeutics Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Gastric Cancer Therapeutics Market, By Region:
    • North America
      • United States
      • Canada
      • Mexico
    • Europe
      • Germany
      • France
      • United Kingdom
      • Italy
      • Spain
    • Asia-Pacific
      • China
      • Japan
      • India
      • South Korea
      • Australia
    • Middle East & Africa
      • South Africa
      • Saudi Arabia
      • UAE
    • South America
      • Brazil
      • Argentina
      • Colombia

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global Gastric Cancer Therapeutics market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).
Global Gastric Cancer Therapeutics Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at sales@techsciresearch.com

1.     Product Overview

2.     Research Methodology

3.     Impact of COVID-19 on Global Gastric Cancer Therapeutics Market

4.     Executive Summary

5.     Voice of Customer

6.     Global Gastric Cancer Therapeutics Market Outlook

6.1.   Market Size & Forecast

6.1.1.      By Value

6.2.   Market Share & Forecast

6.2.1.      By Therapy Type (Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Surgery)

6.2.2.      By Disease Indication (Gastric Adenocarcinoma, Gastrointestinal Stromal Tumor (GIST), Gastric Neuroendocrine Tumors (gNET))

6.2.3.      By Molecule Type (Small Molecule, Biologics)

6.2.4.      By Line of Therapy (Neoadjuvant and Adjuvant, First Line Therapy, Second Line Therapy)

6.2.5.      By Mode of Action (Programmed Cell Death Protein 1 (PD-1) Inhibitors, Human Epidermal Growth Factor Receptor (HER2) Antagonists, Vascular Endothelial Growth Factor Receptor (VEGFR) Antagonists, Others (Microtubule Inhibitors, Kinase Inhibitors))

6.2.6.      By Route of Administration (Oral vs. Parenteral)

6.2.7.      By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)

6.2.8.      By Distribution channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

6.2.9.      By Company (2020)

6.2.10.   By Region

6.3.   Product Market Map

7.     Asia-Pacific Gastric Cancer Therapeutics Market Outlook

7.1.   Market Size & Forecast          

7.1.1.      By Value

7.2.   Market Share & Forecast

7.2.1.      By Therapy Type

7.2.2.      By Disease Indication

7.2.3.      By Molecule Type

7.2.4.      By Line of Therapy

7.2.5.      By Mode of Action

7.2.6.      By Route of Administration

7.2.7.      By End User

7.2.8.      By Distribution Channel

7.2.9.      By Country

7.3.   Asia-Pacific: Country Analysis

7.3.1.      China Gastric Cancer Therapeutics Market Outlook

7.3.1.1.           Market Size & Forecast

7.3.1.1.1.                By Value

7.3.1.2.           Market Share & Forecast

7.3.1.2.1.                By Therapy Type

7.3.1.2.2.                By Disease Indication

7.3.1.2.3.                By Molecule Type

7.3.1.2.4.                By Line of Therapy

7.3.1.2.5.                By Mode of Action

7.3.1.2.6.                By Route of Administration

7.3.1.2.7.                By End User

7.3.1.2.8.                By Distribution Channel

7.3.2.      India Gastric Cancer Therapeutics Market Outlook

7.3.2.1.           Market Size & Forecast

7.3.2.1.1.                By Value

7.3.2.2.           Market Share & Forecast

7.3.2.2.1.                By Therapy Type

7.3.2.2.2.                By Disease Indication

7.3.2.2.3.                By Molecule Type

7.3.2.2.4.                By Line of Therapy

7.3.2.2.5.                By Mode of Action

7.3.2.2.6.                By Route of Administration

7.3.2.2.7.                By End User

7.3.2.2.8.                By Distribution Channel

7.3.3.      Japan Gastric Cancer Therapeutics Market Outlook

7.3.3.1.           Market Size & Forecast

7.3.3.1.1.                By Value

7.3.3.2.           Market Share & Forecast

7.3.3.2.1.                By Therapy Type

7.3.3.2.2.                By Disease Indication

7.3.3.2.3.                By Molecule Type

7.3.3.2.4.                By Line of Therapy

7.3.3.2.5.                By Mode of Action

7.3.3.2.6.                By Route of Administration

7.3.3.2.7.                By End User

7.3.3.2.8.                By Distribution Channel

7.3.4.      South Korea Gastric Cancer Therapeutics Market Outlook

7.3.4.1.           Market Size & Forecast

7.3.4.1.1.                By Value

7.3.4.2.           Market Share & Forecast

7.3.4.2.1.                By Therapy Type

7.3.4.2.2.                By Disease Indication

7.3.4.2.3.                By Molecule Type

7.3.4.2.4.                By Line of Therapy

7.3.4.2.5.                By Mode of Action

7.3.4.2.6.                By Route of Administration

7.3.4.2.7.                By End User

7.3.4.2.8.                By Distribution Channel

7.3.5.      Australia Gastric Cancer Therapeutics Market Outlook

7.3.5.1.           Market Size & Forecast

7.3.5.1.1.                By Value

7.3.5.2.           Market Share & Forecast

7.3.5.2.1.                By Therapy Type

7.3.5.2.2.                By Disease Indication

7.3.5.2.3.                By Molecule Type

7.3.5.2.4.                By Line of Therapy

7.3.5.2.5.                By Mode of Action

7.3.5.2.6.                By Route of Administration

7.3.5.2.7.                By End User

7.3.5.2.8.                By Distribution Channel

8.     Europe Gastric Cancer Therapeutics Market Outlook

8.1.   Market Size & Forecast          

8.1.1.      By Value

8.2.   Market Share & Forecast

8.2.1.      By Therapy Type

8.2.2.      By Disease Indication

8.2.3.      By Molecule Type

8.2.4.      By Line of Therapy

8.2.5.      By Mode of Action

8.2.6.      By Route of Administration

8.2.7.      By End User

8.2.8.      By Distribution Channel

8.2.9.      By Country

8.3.   Europe: Country Analysis

8.3.1.      France Gastric Cancer Therapeutics Market Outlook

8.3.1.1.           Market Size & Forecast

8.3.1.1.1.                By Value

8.3.1.2.           Market Share & Forecast

8.3.1.2.1.                By Therapy Type

8.3.1.2.2.                By Disease Indication

8.3.1.2.3.                By Molecule Type

8.3.1.2.4.                By Line of Therapy

8.3.1.2.5.                By Mode of Action

8.3.1.2.6.                By Route of Administration

8.3.1.2.7.                By End User

8.3.1.2.8.                By Distribution Channel

8.3.2.      Germany Gastric Cancer Therapeutics Market Outlook

8.3.2.1.           Market Size & Forecast

8.3.2.1.1.                By Value

8.3.2.2.           Market Share & Forecast

8.3.2.2.1.                By Therapy Type

8.3.2.2.2.                By Disease Indication

8.3.2.2.3.                By Molecule Type

8.3.2.2.4.                By Line of Therapy

8.3.2.2.5.                By Mode of Action

8.3.2.2.6.                By Route of Administration

8.3.2.2.7.                By End User

8.3.2.2.8.                By Distribution Channel

8.3.3.      United Kingdom Gastric Cancer Therapeutics Market Outlook

8.3.3.1.           Market Size & Forecast

8.3.3.1.1.                By Value

8.3.3.2.           Market Share & Forecast

8.3.3.2.1.                By Therapy Type

8.3.3.2.2.                By Disease Indication

8.3.3.2.3.                By Molecule Type

8.3.3.2.4.                By Line of Therapy

8.3.3.2.5.                By Mode of Action

8.3.3.2.6.                By Route of Administration

8.3.3.2.7.                By End User

8.3.3.2.8.                By Distribution Channel

8.3.4.      Italy Gastric Cancer Therapeutics Market Outlook

8.3.4.1.           Market Size & Forecast

8.3.4.1.1.                By Value

8.3.4.2.           Market Share & Forecast

8.3.4.2.1.                By Therapy Type

8.3.4.2.2.                By Disease Indication

8.3.4.2.3.                By Molecule Type

8.3.4.2.4.                By Line of Therapy

8.3.4.2.5.                By Mode of Action

8.3.4.2.6.                By Route of Administration

8.3.4.2.7.                By End User

8.3.4.2.8.                By Distribution Channel

8.3.5.      Spain Gastric Cancer Therapeutics Market Outlook

8.3.5.1.           Market Size & Forecast

8.3.5.1.1.                By Value

8.3.5.2.           Market Share & Forecast

8.3.5.2.1.                By Therapy Type

8.3.5.2.2.                By Disease Indication

8.3.5.2.3.                By Molecule Type

8.3.5.2.4.                By Line of Therapy

8.3.5.2.5.                By Mode of Action

8.3.5.2.6.                By Route of Administration

8.3.5.2.7.                By End User

8.3.5.2.8.                By Distribution Channel

9.     North America Gastric Cancer Therapeutics Market Outlook

9.1.   Market Size & Forecast          

9.1.1.      By Value

9.2.   Market Share & Forecast

9.2.1.      By Therapy Type

9.2.2.      By Disease Indication

9.2.3.      By Molecule Type

9.2.4.      By Line of Therapy

9.2.5.      By Mode of Action

9.2.6.      By Route of Administration

9.2.7.      By End User

9.2.8.      By Distribution Channel

9.2.9.      By Country

9.3.   North America: Country Analysis

9.3.1.      United States Gastric Cancer Therapeutics Market Outlook

9.3.1.1.           Market Size & Forecast

9.3.1.1.1.                By Value

9.3.1.2.           Market Share & Forecast

9.3.1.2.1.                By Therapy Type

9.3.1.2.2.                By Disease Indication

9.3.1.2.3.                By Molecule Type

9.3.1.2.4.                By Line of Therapy

9.3.1.2.5.                By Mode of Action

9.3.1.2.6.                By Route of Administration

9.3.1.2.7.                By End User

9.3.1.2.8.                By Distribution Channel

9.3.2.      Mexico Gastric Cancer Therapeutics Market Outlook

9.3.2.1.           Market Size & Forecast

9.3.2.1.1.                By Value

9.3.2.2.           Market Share & Forecast

9.3.2.2.1.                By Therapy Type

9.3.2.2.2.                By Disease Indication

9.3.2.2.3.                By Molecule Type

9.3.2.2.4.                By Line of Therapy

9.3.2.2.5.                By Mode of Action

9.3.2.2.6.                By Route of Administration

9.3.2.2.7.                By End User

9.3.2.2.8.                By Distribution Channel

9.3.3.      Canada Gastric Cancer Therapeutics Market Outlook

9.3.3.1.           Market Size & Forecast

9.3.3.1.1.                By Value

9.3.3.2.           Market Share & Forecast

9.3.3.2.1.                By Therapy Type

9.3.3.2.2.                By Disease Indication

9.3.3.2.3.                By Molecule Type

9.3.3.2.4.                By Line of Therapy

9.3.3.2.5.                By Mode of Action

9.3.3.2.6.                By Route of Administration

9.3.3.2.7.                By End User

9.3.3.2.8.                By Distribution Channel

10.  South America Gastric Cancer Therapeutics Market Outlook

10.1.                 Market Size & Forecast

10.1.1.   By Value

10.2.                 Market Share & Forecast

10.2.1.   By Therapy Type

10.2.2.   By Disease Indication

10.2.3.   By Molecule Type

10.2.4.   By Line of Therapy

10.2.5.   By Mode of Action

10.2.6.   By Route of Administration

10.2.7.   By End User

10.2.8.   By Distribution Channel

10.2.9.   By Country

10.3.                 South America: Country Analysis

10.3.1.   Brazil Gastric Cancer Therapeutics Market Outlook

10.3.1.1.        Market Size & Forecast

10.3.1.1.1.             By Value

10.3.1.2.        Market Share & Forecast

10.3.1.2.1.             By Therapy Type

10.3.1.2.2.             By Disease Indication

10.3.1.2.3.             By Molecule Type

10.3.1.2.4.             By Line of Therapy

10.3.1.2.5.             By Mode of Action

10.3.1.2.6.             By Route of Administration

10.3.1.2.7.             By End User

10.3.1.2.8.             By Distribution Channel

10.3.2.   Argentina Gastric Cancer Therapeutics Market Outlook

10.3.2.1.        Market Size & Forecast

10.3.2.1.1.             By Value

10.3.2.2.        Market Share & Forecast

10.3.2.2.1.             By Therapy Type

10.3.2.2.2.             By Disease Indication

10.3.2.2.3.             By Molecule Type

10.3.2.2.4.             By Line of Therapy

10.3.2.2.5.             By Mode of Action

10.3.2.2.6.             By Route of Administration

10.3.2.2.7.             By End User

10.3.2.2.8.             By Distribution Channel

10.3.3.   Colombia Gastric Cancer Therapeutics Market Outlook

10.3.3.1.        Market Size & Forecast

10.3.3.1.1.             By Value

10.3.3.2.        Market Share & Forecast

10.3.3.2.1.             By Therapy Type

10.3.3.2.2.             By Disease Indication

10.3.3.2.3.             By Molecule Type

10.3.3.2.4.             By Line of Therapy

10.3.3.2.5.             By Mode of Action